Still the Great Debate - "Fair Balance" in Direct-to-Consumer Prescription Drug Advertising; Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters"
Document Type
Letter to the Editor
Publication Date
2016
Abstract
The above titled paper examined the Food and Drug Administration's (FDA's) warning letters and notice of violations (NOV) over a 10-year period. Findings from this content analysis reinforced what has been the primary issue for prescription direct-to-consumer advertising (DTCA) since its beginning, the fair balance of risk and benefit information. As opposed to another analysis in 2026 about this still being an issue, is there anything that can be done to prevent this problem from continuing?
Publication Title
International Journal of Health Policy and Management
Volume
5
Issue
4
First Page
287
Last Page
288
Recommended Citation
Rollins, Brent L., "Still the Great Debate - "Fair Balance" in Direct-to-Consumer Prescription Drug Advertising; Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters"" (2016). PCOM Scholarly Works. 1689.
https://digitalcommons.pcom.edu/scholarly_papers/1689
Comments
This letter was published in International Journal of Health Policy and Management, Volume 5, Issue 4, Pages 287-288.
The published version is available at http://dx.doi.org/10.15171/ijhpm.2016.17.Copyright © 2016.